Trials in the sirolimus (and analogues) subgroup
|
RAVEL38 | Sirolimus | 1 year | Clopidogrel or ticlopidine 8 weeks | TLR: clinically driven or evidence of restenosis | In-target lesion including proximal and distal edge; at 6 months | Any |
SIRIUS39 | Sirolimus | 1 year | Clopidogrel 3 months | TLR: clinically driven and restenosis >70% | In segment zone including margins 5 mm distal and proximal; at 8 months | Any |
E-SIRIUS40 | Sirolimus | 9 months | Clopidogrel or ticlopidine 2 months | TLR: clinically driven | In lesion including 5 mm proximal and distal edge; at 8 months | Any |
C-SIRIUS41,42 | Sirolimus | 1 year | Clopidogrel 2 months | TLR: clinically driven including stenosis >70% | In-stent lesion; at 8 months | Any |
FUTURE I/II45 | Everolimus | 6 months | NA | TLR | In segment; at 6 months | Any |
SES-SMART59 | Sirolimus | 8 months | Clopidogrel 2 months | TLR | In segment; at 8 months | Any |
SCANDSTENT44 | Sirolimus | 1 year | NA | TLR | In-stent lesion; at 6 months | Any |
DIABETES43 | Sirolimus | 9 months | NA | TLR | In segment; at 9 months | Any |
ENDEAVOR II10 | Biolimus | 1 year | NA | TVR | | Any |
Trials in the paclitaxel (and analogues) subgroup
|
SCORE46 | QP2 is 7-hexanoyltaxol | 1 year | Ticlopidine or clopidogrel 1–6 months | TLR | In stent; at 6 months | Cardiac death |
TAXUS I47,48 | Slow release polymer based paclitaxel | 1 year | Clopidogrel 6 months | TVR: indication not reported, only Q wave MI | In-stent lesion (edges excluded); at 6 months | Any |
ASPECT52 | Non-polymer based paclitaxel low or high dose | 6 months | Clopidogrel or ticlopidine 1 or 6 months, or cilostazol | TLR: ischaemia driven | Including proximal and distal references; at 4–6 months | Any |
TAXUS II48,49 | Slow or moderate release polymer based paclitaxel | 1 year | Clopidogrel (or ticlopidine) 6 months | TVR: indication not reported | In total analysis segment including 5 mm proximal and distal edge; at 6 months | Cardiac death |
TAXUS IV48,60 | Slow release polymer based paclitaxel | 9 months | Clopidogrel for 6 months | TVR: ischaemia driven | In analysis segment including proximal and distal edge; at 9 months | Cardiac death |
ELUTES55 | Non-polymer based paclitaxel 4 doses | 1 year | Clopidogrel 3 months | TLR: clinically driven | In stent; at 6 months | Any |
DELIVER53,54 | Non-polymer based paclitaxel | 1 year | Clopidogrel 3 months | TVR | In segment including 5 mm proximal and distal; at 8 months | Cardiac death |
PATENCY56 | Non-polymer based paclitaxel | 9 months | Clopidogrel 3 month | TLR | In stent? At 9 months | Any |
TAXUS V61 | Slow release polymer based paclitaxel | 9 months | NA | TVR: indication not reported | In stent? At 9 months | Cardiac death |
TAXUS VI62 | Moderate release polymer based paclitaxel | 9 months | NA | TVR: indication not reported | In segment? At 9 months | Cardiac death |